Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 21 01:15PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-7.14 Insider Own7.38% Shs Outstand3.94M Perf Week2.49%
Market Cap2.09M Forward P/E- EPS next Y-1.41 Insider Trans0.00% Shs Float3.65M Perf Month-2.75%
Income-18.03M PEG- EPS next Q-0.67 Inst Own6.67% Short Float0.23% Perf Quarter-23.19%
Sales0.00M P/S- EPS this Y66.53% Inst Trans-3.64% Short Ratio0.26 Perf Half Y-41.11%
Book/sh1.54 P/B0.34 EPS next Y71.69% ROA-128.22% Short Interest0.01M Perf Year-76.23%
Cash/sh1.92 P/C0.28 EPS next 5Y- ROE-158.90% 52W Range0.50 - 2.68 Perf YTD-18.46%
Dividend Est.- P/FCF- EPS past 5Y58.74% ROI-296.40% 52W High-80.22% Beta0.98
Dividend TTM- Quick Ratio3.59 Sales past 5Y-9.06% Gross Margin- 52W Low6.00% ATR (14)0.07
Dividend Ex-Date- Current Ratio3.59 EPS Y/Y TTM5.87% Oper. Margin0.00% RSI (14)42.23 Volatility17.98% 11.29%
Employees12 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price3.25
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q89.85% Payout- Rel Volume2.52 Prev Close0.57
Sales Surprise- EPS Surprise- Sales Q/Q- EarningsAug 10 AMC Avg Volume32.18K Price0.53
SMA20-4.45% SMA50-10.94% SMA200-42.10% Trades Volume50,024 Change-6.29%
Date Action Analyst Rating Change Price Target Change
Apr-27-20Initiated Ladenburg Thalmann Buy $3.80
Jan-16-24 08:00AM
Jan-03-24 08:30AM
Nov-10-23 05:03AM
Nov-07-23 08:30AM
Aug-10-23 05:10PM
04:05PM Loading…
Aug-09-23 07:39AM
Aug-08-23 04:05PM
Jul-11-23 09:00AM
Jun-12-23 08:00AM
May-16-23 04:05PM
May-12-23 08:00AM
May-11-23 08:20AM
08:00AM Loading…
May-09-23 08:00AM
May-01-23 08:30AM
Apr-20-23 08:30AM
Apr-04-23 04:02PM
Mar-27-23 08:30AM
Mar-15-23 11:00AM
Mar-07-23 08:00AM
Feb-16-23 08:30AM
Jan-27-23 08:30AM
Jan-19-23 08:30AM
Jan-05-23 08:00AM
Dec-13-22 08:01AM
08:00AM Loading…
Dec-08-22 08:00AM
Dec-01-22 08:00AM
Nov-10-22 08:30AM
Nov-03-22 09:57AM
Oct-27-22 08:30AM
Oct-19-22 08:30AM
Oct-18-22 08:30AM
Oct-14-22 08:43AM
Sep-20-22 12:00PM
Sep-13-22 08:00AM
Aug-22-22 08:30AM
Aug-08-22 08:30AM
Aug-04-22 08:30AM
Aug-02-22 08:30AM
Jul-29-22 09:15AM
Jun-09-22 07:33AM
May-18-22 04:10PM
May-12-22 04:05PM
May-11-22 04:05PM
May-05-22 07:30AM
Apr-22-22 08:30AM
Mar-10-22 04:05PM
Mar-03-22 07:31AM
Feb-17-22 08:01AM
Feb-15-22 09:00AM
Feb-08-22 08:00AM
Feb-03-22 07:30AM
Jan-14-22 01:52PM
Jan-13-22 07:00AM
Jan-06-22 12:45PM
Dec-29-21 08:03AM
Dec-20-21 08:35AM
Dec-15-21 08:31AM
Dec-14-21 08:35AM
Nov-29-21 08:01AM
Nov-04-21 04:05PM
Oct-28-21 03:06PM
Oct-26-21 08:01AM
Oct-07-21 09:05AM
Oct-05-21 08:01AM
Sep-30-21 04:35PM
Sep-28-21 07:01AM
Sep-27-21 08:03AM
Sep-22-21 07:33AM
Sep-20-21 08:35AM
Sep-15-21 08:03AM
Sep-10-21 08:35AM
Sep-08-21 08:13AM
Aug-12-21 02:00PM
Aug-10-21 06:16AM
Aug-05-21 07:32AM
Jul-29-21 07:33AM
Jul-14-21 08:05AM
Jul-13-21 07:33AM
Jul-09-21 07:33AM
Jun-17-21 08:03AM
Jun-15-21 07:30AM
Jun-10-21 01:30PM
Jun-07-21 07:35AM
May-19-21 05:01PM
May-12-21 04:05PM
May-05-21 07:05AM
Apr-29-21 07:30AM
Apr-19-21 07:30AM
Mar-18-21 04:05PM
Mar-11-21 04:15PM
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.